Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab

Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huanyu, Xie, Xiaoxi, Zhang, Tianyu, Yang, Menghan, Zhou, Dong, Yang, Tianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990884/
https://www.ncbi.nlm.nih.gov/pubmed/35401563
http://dx.doi.org/10.3389/fimmu.2022.850540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990884/
https://www.ncbi.nlm.nih.gov/pubmed/35401563
http://dx.doi.org/10.3389/fimmu.2022.850540

Ejemplares similares